Bruker (NASDAQ:BRKR) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Tuesday, BidAskClub reports.

BRKR has been the subject of several other research reports. BTIG Research lifted their price target on shares of Bruker to $57.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Needham & Company LLC lifted their price objective on shares of from $50.00 to $53.00 in a report on Monday, June 24th. Zacks Investment Research downgraded shares of Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. UBS Group set a $125.00 price objective on shares of Caterpillar and gave the stock a “sell” rating in a report on Friday, May 3rd. Finally, Bank of America set a $300.00 price objective on shares of IDEXX Laboratories and gave the stock a “buy” rating in a report on Friday, June 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Bruker currently has a consensus rating of “Buy” and a consensus target price of $48.18.

NASDAQ BRKR opened at $48.48 on Tuesday. The company has a fifty day simple moving average of $47.18. Bruker has a 12-month low of $26.10 and a 12-month high of $51.41. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. The firm has a market cap of $7.78 billion, a P/E ratio of 34.45, a P/E/G ratio of 2.43 and a beta of 1.32.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The business had revenue of $461.40 million during the quarter, compared to the consensus estimate of $450.46 million. During the same quarter last year, the firm posted $0.24 EPS. Bruker’s revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bruker will post 1.62 EPS for the current fiscal year.

In other news, CEO Frank H. Laukien sold 400,000 shares of Bruker stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the sale, the chief executive officer now directly owns 37,991,030 shares in the company, valued at approximately $1,575,867,924.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marc A. Kastner sold 1,374 shares of Bruker stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $41.79, for a total value of $57,419.46. Following the sale, the director now owns 10,811 shares in the company, valued at $451,791.69. The disclosure for this sale can be found here. Insiders have sold a total of 801,374 shares of company stock worth $33,241,419 over the last ninety days. Insiders own 26.50% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Comerica Bank bought a new stake in Bruker during the fourth quarter worth approximately $219,000. BlackRock Inc. boosted its holdings in Bruker by 2.6% during the fourth quarter. BlackRock Inc. now owns 5,465,722 shares of the medical research company’s stock worth $162,713,000 after buying an additional 139,004 shares in the last quarter. Raymond James & Associates boosted its holdings in Bruker by 16.1% during the fourth quarter. Raymond James & Associates now owns 15,370 shares of the medical research company’s stock worth $458,000 after buying an additional 2,128 shares in the last quarter. Northern Trust Corp boosted its holdings in Bruker by 14.3% during the fourth quarter. Northern Trust Corp now owns 633,484 shares of the medical research company’s stock worth $18,859,000 after buying an additional 79,482 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its holdings in Bruker by 15.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 12,537 shares of the medical research company’s stock worth $360,000 after buying an additional 1,708 shares in the last quarter. Institutional investors own 66.73% of the company’s stock.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Recommended Story: The role of implied volatility with call option volume

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.